Difference between revisions of "Team:Ecuador"
Tefiducky8 (Talk | contribs) |
Tefiducky8 (Talk | contribs) |
||
| (13 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Ecuador}} | {{Ecuador}} | ||
| + | {{Ecuador/slide_script}} | ||
<html> | <html> | ||
<style> | <style> | ||
| Line 199: | Line 200: | ||
animation-delay: 1s; | animation-delay: 1s; | ||
animation-fill-mode: backwards; | animation-fill-mode: backwards; | ||
| + | |||
position: absolute; | position: absolute; | ||
left: 62.5%; | left: 62.5%; | ||
| Line 334: | Line 336: | ||
.ecuador_follow_us_icons_container { | .ecuador_follow_us_icons_container { | ||
| − | + | width: 50%; | |
| − | + | height: 60px; | |
| − | + | position: relative; | |
| − | + | top: 40px; | |
| − | + | margin: auto; | |
| − | + | display: flex; | |
| − | + | ||
} | } | ||
.ecuador_information_data_container{ | .ecuador_information_data_container{ | ||
| Line 416: | Line 417: | ||
margin-top: 10px; | margin-top: 10px; | ||
background-color: #FFF; | background-color: #FFF; | ||
| − | + | ||
background-position: center; | background-position: center; | ||
background-repeat: no-repeat; | background-repeat: no-repeat; | ||
| Line 471: | Line 472: | ||
animation-fill-mode: backwards; | animation-fill-mode: backwards; | ||
display: none; | display: none; | ||
| + | line-height: 1; | ||
} | } | ||
| Line 487: | Line 489: | ||
animation-fill-mode: backwards; | animation-fill-mode: backwards; | ||
display: none; | display: none; | ||
| + | line-height: 1; | ||
} | } | ||
| − | |||
.ecuador_down_arrow_container_description { | .ecuador_down_arrow_container_description { | ||
width: 130px; | width: 130px; | ||
| Line 556: | Line 558: | ||
animation-fill-mode: backwards; | animation-fill-mode: backwards; | ||
display: none; | display: none; | ||
| + | line-height: 2.6; | ||
} | } | ||
| Line 648: | Line 651: | ||
.ecuador_sponsors_icons_container { | .ecuador_sponsors_icons_container { | ||
| − | + | width: 100%; | |
| − | + | height: 60px; | |
| − | + | position: relative; | |
| − | + | top: 40px; | |
| − | + | margin: auto; | |
| − | + | display: flex; | |
} | } | ||
.ecuador_sponsors_icon { | .ecuador_sponsors_icon { | ||
| − | + | width: 60px; | |
| − | + | height: 60px; | |
| − | + | position: relative; | |
| − | + | margin-right: 4px; | |
| + | margin-left: 4px; | ||
} | } | ||
#ing_bio{ | #ing_bio{ | ||
| Line 708: | Line 712: | ||
background-size: 93%; | background-size: 93%; | ||
cursor: pointer; | cursor: pointer; | ||
| − | } | + | } |
| − | + | #slider_Part_Law_2{ | |
| + | max-width: 1200px; | ||
| + | margin: 50px auto; | ||
| + | } | ||
</style> | </style> | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
<div class="ecuador_home_content"> | <div class="ecuador_home_content"> | ||
<div class="ecuador_team_icon"> | <div class="ecuador_team_icon"> | ||
| − | + | <div id="slider_Part_Law_2"> | |
| + | <img src="https://static.igem.org/mediawiki/2018/6/65/T--Ecuador--logo_clastin-2.png" height="80%" /> | ||
| + | <img data-src="https://static.igem.org/mediawiki/2018/3/33/T--Ecuador--Logo--003.png" src="" height="80%"/> | ||
| + | <img data-src="https://static.igem.org/mediawiki/2018/3/33/T--Ecuador--jamboree.jpg" src="" height="80%"/> | ||
| + | <img data-src="https://static.igem.org/mediawiki/2018/d/d5/T--Ecuador--group.jpeg" src="" height="80%"/> | ||
| + | <img data-src="https://static.igem.org/mediawiki/2018/1/13/T--Ecuador--airp.jpeg" src="" height="80%"/> | ||
| + | </div> | ||
</div> | </div> | ||
<div onclick="scrollToDescriptionVideo()" class="ecuador_down_arrow_container"> | <div onclick="scrollToDescriptionVideo()" class="ecuador_down_arrow_container"> | ||
| Line 907: | Line 755: | ||
</div> | </div> | ||
<div id="ecuador_description_abstract_text_container" class="ecuador_description_abstract_text_container"> | <div id="ecuador_description_abstract_text_container" class="ecuador_description_abstract_text_container"> | ||
| − | + | We are developing a novel biomaterial for biomedical applications based on the cross-linking of bacterial cellulose (BC) and a fusion protein with modules carbohydrate binding domain (CBD) for binding to cellulose, elastin-like polypeptides (ELP) and bone morphogenic protein 2 (BMP-2). The production of this biomaterial is being carried out with synthetic biology techniques using two differents Escherichia coli expression systems. The first one produces bacterial celullose and the second one produces the fusion protein CBD-ELP-BMP2. | |
<br/> | <br/> | ||
<br/> | <br/> | ||
| − | Bacterial cellulose | + | |
| + | Bacterial cellulose is used as a matrix because of the biocompatibility with the human body and has the potential to regulate cell adhesion, that is an important characteristic to be used as a scaffold. ELP is a structural protein which confers new physicochemical characteristics to the biomaterial such us a transition temperature that allows the biomaterial to be as a hydrogel. On the other hand, the BMP2 protein, is an inducer of cell differentiation in osteoblasts, which confers bone tissue regeneration property. | ||
| + | |||
| + | |||
<br/> | <br/> | ||
<br/> | <br/> | ||
| − | + | ||
</div> | </div> | ||
</div> | </div> | ||
| Line 919: | Line 770: | ||
</div> | </div> | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| + | <script> | ||
| + | |||
| + | var slider_Part_Law_2 = new IdealImageSlider.Slider({ | ||
| + | selector: '#slider_Part_Law_2', | ||
| + | height: 600, // Required but can be set by CSS | ||
| + | initialHeight: 600, | ||
| + | maxHeight: 750, | ||
| + | interval: 4000 | ||
| + | }); | ||
| + | //slider_Part_Law_2.addCaptions(); | ||
| + | slider_Part_Law_2.start(); | ||
| + | |||
| + | </script> | ||
<script type="text/javascript"> | <script type="text/javascript"> | ||
| Line 996: | Line 818: | ||
</script> | </script> | ||
| + | |||
</html> | </html> | ||
| + | {{Ecuador/footer}} | ||
Latest revision as of 18:26, 25 November 2018
IdealImageSlider
Captions Extension v1.0.1
![]()
![]()
![]()
![]()
What is C-lastin?
Know our idea
About our project
We are developing a novel biomaterial for biomedical applications based on the cross-linking of bacterial cellulose (BC) and a fusion protein with modules carbohydrate binding domain (CBD) for binding to cellulose, elastin-like polypeptides (ELP) and bone morphogenic protein 2 (BMP-2). The production of this biomaterial is being carried out with synthetic biology techniques using two differents Escherichia coli expression systems. The first one produces bacterial celullose and the second one produces the fusion protein CBD-ELP-BMP2.
Bacterial cellulose is used as a matrix because of the biocompatibility with the human body and has the potential to regulate cell adhesion, that is an important characteristic to be used as a scaffold. ELP is a structural protein which confers new physicochemical characteristics to the biomaterial such us a transition temperature that allows the biomaterial to be as a hydrogel. On the other hand, the BMP2 protein, is an inducer of cell differentiation in osteoblasts, which confers bone tissue regeneration property.
Bacterial cellulose is used as a matrix because of the biocompatibility with the human body and has the potential to regulate cell adhesion, that is an important characteristic to be used as a scaffold. ELP is a structural protein which confers new physicochemical characteristics to the biomaterial such us a transition temperature that allows the biomaterial to be as a hydrogel. On the other hand, the BMP2 protein, is an inducer of cell differentiation in osteoblasts, which confers bone tissue regeneration property.